Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo

Rei Suzuki, Hirofumi Yamamoto, Chew Yee Ngan, Masahisa Ohtsuka, Kotaro Kitani, Mamoru Uemura, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Mitsugu Sekimoto, Toshinari Minamoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Anti-angiogenic therapy, inhibition of a co-operative process with vascular endothelial cells and pericytes could be an effective strategy to treat malignant tumours. Apart from vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2) is a promising target of anti-angiogenic therapy. Although inhibition of Ang2 has been shown to decrease tumour size in preclinical and phase I trials, its mechanisms of action remain largely unknown. To elucidate the mechanisms of Ang2 inhibition, we have focused on differentiation of the vessels as well as on growth of the vessels, especially in vivo. L1-10, a selective Ang2 inhibitor was used. The in vitro effects of Ang2 inhibition or addition of Ang2 using HUVECs were also examined. Growth and differentiation of tumour-associated vessels were investigated in xenografts derived from a colon cancer treated by L1-10. Effects of VEGF inhibition were also examined to discriminate Ang2-specific action on the tumour-associated vessels. In vitro studies showed that VEGF enhanced proliferation and tube formation of HUVECs, and caused a significant increase in Rac1 and CDC42 expression when cultured in the collagen matrix gel, whereas neither Ang2 nor L1-10 affected in vitro behaviour of HUVECs or levels of the proteins. In vivo, on the other hand, we found that Ang2 inhibition with treatment of L1-10 dose-dependently decreased tumour growth. Furthermore, we found that L1-10 treatment extends the tumour-associated vessels whilst it suppressed a sound lumen formation. Histological analysis on xenografts suggests that Ang2 inhibition could have disturbed in vivo vascular differentiation. Our data provide a novel aspect that Ang2 may play an essential role in in vivo vascular differentiation, thus supporting a rationale for Ang2-targeted therapy against colon cancer.

Original languageEnglish
Pages (from-to)1447-1455
Number of pages9
JournalInternational journal of oncology
Volume43
Issue number5
DOIs
Publication statusPublished - Nov 1 2013
Externally publishedYes

Fingerprint

Angiopoietin-2
Neoplasms
Vascular Endothelial Growth Factor A
Heterografts
Colonic Neoplasms
Blood Vessels
Growth
Pericytes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo. / Suzuki, Rei; Yamamoto, Hirofumi; Ngan, Chew Yee; Ohtsuka, Masahisa; Kitani, Kotaro; Uemura, Mamoru; Nishimura, Junichi; Takemasa, Ichiro; Mizushima, Tsunekazu; Sekimoto, Mitsugu; Minamoto, Toshinari; Doki, Yuichiro; Mori, Masaki.

In: International journal of oncology, Vol. 43, No. 5, 01.11.2013, p. 1447-1455.

Research output: Contribution to journalArticle

Suzuki, R, Yamamoto, H, Ngan, CY, Ohtsuka, M, Kitani, K, Uemura, M, Nishimura, J, Takemasa, I, Mizushima, T, Sekimoto, M, Minamoto, T, Doki, Y & Mori, M 2013, 'Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo', International journal of oncology, vol. 43, no. 5, pp. 1447-1455. https://doi.org/10.3892/ijo.2013.2076
Suzuki, Rei ; Yamamoto, Hirofumi ; Ngan, Chew Yee ; Ohtsuka, Masahisa ; Kitani, Kotaro ; Uemura, Mamoru ; Nishimura, Junichi ; Takemasa, Ichiro ; Mizushima, Tsunekazu ; Sekimoto, Mitsugu ; Minamoto, Toshinari ; Doki, Yuichiro ; Mori, Masaki. / Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo. In: International journal of oncology. 2013 ; Vol. 43, No. 5. pp. 1447-1455.
@article{cfe72edffb7d4e64ad8b1b570c3101c6,
title = "Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo",
abstract = "Anti-angiogenic therapy, inhibition of a co-operative process with vascular endothelial cells and pericytes could be an effective strategy to treat malignant tumours. Apart from vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2) is a promising target of anti-angiogenic therapy. Although inhibition of Ang2 has been shown to decrease tumour size in preclinical and phase I trials, its mechanisms of action remain largely unknown. To elucidate the mechanisms of Ang2 inhibition, we have focused on differentiation of the vessels as well as on growth of the vessels, especially in vivo. L1-10, a selective Ang2 inhibitor was used. The in vitro effects of Ang2 inhibition or addition of Ang2 using HUVECs were also examined. Growth and differentiation of tumour-associated vessels were investigated in xenografts derived from a colon cancer treated by L1-10. Effects of VEGF inhibition were also examined to discriminate Ang2-specific action on the tumour-associated vessels. In vitro studies showed that VEGF enhanced proliferation and tube formation of HUVECs, and caused a significant increase in Rac1 and CDC42 expression when cultured in the collagen matrix gel, whereas neither Ang2 nor L1-10 affected in vitro behaviour of HUVECs or levels of the proteins. In vivo, on the other hand, we found that Ang2 inhibition with treatment of L1-10 dose-dependently decreased tumour growth. Furthermore, we found that L1-10 treatment extends the tumour-associated vessels whilst it suppressed a sound lumen formation. Histological analysis on xenografts suggests that Ang2 inhibition could have disturbed in vivo vascular differentiation. Our data provide a novel aspect that Ang2 may play an essential role in in vivo vascular differentiation, thus supporting a rationale for Ang2-targeted therapy against colon cancer.",
author = "Rei Suzuki and Hirofumi Yamamoto and Ngan, {Chew Yee} and Masahisa Ohtsuka and Kotaro Kitani and Mamoru Uemura and Junichi Nishimura and Ichiro Takemasa and Tsunekazu Mizushima and Mitsugu Sekimoto and Toshinari Minamoto and Yuichiro Doki and Masaki Mori",
year = "2013",
month = "11",
day = "1",
doi = "10.3892/ijo.2013.2076",
language = "English",
volume = "43",
pages = "1447--1455",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo

AU - Suzuki, Rei

AU - Yamamoto, Hirofumi

AU - Ngan, Chew Yee

AU - Ohtsuka, Masahisa

AU - Kitani, Kotaro

AU - Uemura, Mamoru

AU - Nishimura, Junichi

AU - Takemasa, Ichiro

AU - Mizushima, Tsunekazu

AU - Sekimoto, Mitsugu

AU - Minamoto, Toshinari

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Anti-angiogenic therapy, inhibition of a co-operative process with vascular endothelial cells and pericytes could be an effective strategy to treat malignant tumours. Apart from vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2) is a promising target of anti-angiogenic therapy. Although inhibition of Ang2 has been shown to decrease tumour size in preclinical and phase I trials, its mechanisms of action remain largely unknown. To elucidate the mechanisms of Ang2 inhibition, we have focused on differentiation of the vessels as well as on growth of the vessels, especially in vivo. L1-10, a selective Ang2 inhibitor was used. The in vitro effects of Ang2 inhibition or addition of Ang2 using HUVECs were also examined. Growth and differentiation of tumour-associated vessels were investigated in xenografts derived from a colon cancer treated by L1-10. Effects of VEGF inhibition were also examined to discriminate Ang2-specific action on the tumour-associated vessels. In vitro studies showed that VEGF enhanced proliferation and tube formation of HUVECs, and caused a significant increase in Rac1 and CDC42 expression when cultured in the collagen matrix gel, whereas neither Ang2 nor L1-10 affected in vitro behaviour of HUVECs or levels of the proteins. In vivo, on the other hand, we found that Ang2 inhibition with treatment of L1-10 dose-dependently decreased tumour growth. Furthermore, we found that L1-10 treatment extends the tumour-associated vessels whilst it suppressed a sound lumen formation. Histological analysis on xenografts suggests that Ang2 inhibition could have disturbed in vivo vascular differentiation. Our data provide a novel aspect that Ang2 may play an essential role in in vivo vascular differentiation, thus supporting a rationale for Ang2-targeted therapy against colon cancer.

AB - Anti-angiogenic therapy, inhibition of a co-operative process with vascular endothelial cells and pericytes could be an effective strategy to treat malignant tumours. Apart from vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2) is a promising target of anti-angiogenic therapy. Although inhibition of Ang2 has been shown to decrease tumour size in preclinical and phase I trials, its mechanisms of action remain largely unknown. To elucidate the mechanisms of Ang2 inhibition, we have focused on differentiation of the vessels as well as on growth of the vessels, especially in vivo. L1-10, a selective Ang2 inhibitor was used. The in vitro effects of Ang2 inhibition or addition of Ang2 using HUVECs were also examined. Growth and differentiation of tumour-associated vessels were investigated in xenografts derived from a colon cancer treated by L1-10. Effects of VEGF inhibition were also examined to discriminate Ang2-specific action on the tumour-associated vessels. In vitro studies showed that VEGF enhanced proliferation and tube formation of HUVECs, and caused a significant increase in Rac1 and CDC42 expression when cultured in the collagen matrix gel, whereas neither Ang2 nor L1-10 affected in vitro behaviour of HUVECs or levels of the proteins. In vivo, on the other hand, we found that Ang2 inhibition with treatment of L1-10 dose-dependently decreased tumour growth. Furthermore, we found that L1-10 treatment extends the tumour-associated vessels whilst it suppressed a sound lumen formation. Histological analysis on xenografts suggests that Ang2 inhibition could have disturbed in vivo vascular differentiation. Our data provide a novel aspect that Ang2 may play an essential role in in vivo vascular differentiation, thus supporting a rationale for Ang2-targeted therapy against colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=84885038176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885038176&partnerID=8YFLogxK

U2 - 10.3892/ijo.2013.2076

DO - 10.3892/ijo.2013.2076

M3 - Article

C2 - 23982687

AN - SCOPUS:84885038176

VL - 43

SP - 1447

EP - 1455

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -